DK1675578T3 - Inhibitorer af glutaminyl- og glutamatcyclaser til behandling af de neurodegenerative sygdomme FBD og FDD - Google Patents

Inhibitorer af glutaminyl- og glutamatcyclaser til behandling af de neurodegenerative sygdomme FBD og FDD

Info

Publication number: DK1675578T3
Authority: DK; Denmark
Prior art keywords: fbd; glutaminyl; fdd; inhibitors; treatment
Prior art date: 2003-10-15

Application number

DK04765975.0T

Other languages

English (en)

Inventor

Stephan Schilling

Torsten Hoffmann

Andre Johannes Niestroj

Hans-Ulrich Demuth

Ulrich Heiser

Original Assignee

Probiodrug Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-15

Filing date

2004-10-15

Publication date

2013-08-26

2004-10-15 Application filed by Probiodrug Ag filed Critical Probiodrug Ag

2013-08-26 Application granted granted Critical

2013-08-26 Publication of DK1675578T3 publication Critical patent/DK1675578T3/da

Links

101710095468 Cyclase Proteins 0.000 title 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 title 1
229930195712 glutamate Natural products 0.000 title 1
125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
230000004770 neurodegeneration Effects 0.000 title 1
208000015122 neurodegenerative disease Diseases 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
Gastroenterology & Hepatology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Communicable Diseases (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Oncology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Hydrogenated Pyridines (AREA)
Enzymes And Modification Thereof (AREA)
Plural Heterocyclic Compounds (AREA)
Peptides Or Proteins (AREA)

DK04765975.0T 2003-10-15 2004-10-15 Inhibitorer af glutaminyl- og glutamatcyclaser til behandling af de neurodegenerative sygdomme FBD og FDD DK1675578T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US51203803P	2003-10-15	2003-10-15
PCT/EP2004/011630 WO2005039548A2 (en)	2003-10-15	2004-10-15	Use of effectors of glutaminyl and glutamate cyclases

Publications (1)

Publication Number	Publication Date
DK1675578T3 true DK1675578T3 (da)	2013-08-26

Family

ID=34520046

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK04765975.0T DK1675578T3 (da)	2003-10-15	2004-10-15	Inhibitorer af glutaminyl- og glutamatcyclaser til behandling af de neurodegenerative sygdomme FBD og FDD

Country Status (14)

Country	Link
US (2)	US7462599B2 (da)
EP (2)	EP2289498A1 (da)
JP (2)	JP5707014B2 (da)
KR (3)	KR101313975B1 (da)
CN (2)	CN102302781A (da)
AU (1)	AU2004283461B2 (da)
BR (1)	BRPI0415409A (da)
CA (1)	CA2542419C (da)
DK (1)	DK1675578T3 (da)
EA (1)	EA010108B1 (da)
IL (1)	IL174372A (da)
MX (1)	MXPA06003998A (da)
NZ (1)	NZ546322A (da)
WO (1)	WO2005039548A2 (da)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA200508439B (en) *	2003-05-05	2007-03-28	Probiodrug Ag	Medical use of inhibitors of glutaminyl and glutamate cyclases
US8338120B2 (en)	2003-05-05	2012-12-25	Probiodrug Ag	Method of treating inflammation with glutaminyl cyclase inhibitors
KR20110059664A (ko) *	2003-05-05	2011-06-02	프로비오드룩 아게	글루타미닐 및 글루타메이트 사이클라제의 이펙터의 용도
MXPA06003998A (es)	2003-10-15	2006-06-27	Probiodrug Ag	Uso de efectores de ciclasas de glutamato y glutaminil.
US20050137142A1 (en) *	2003-11-03	2005-06-23	Probiodrug Ag	Combinations useful for the treatment of neuronal disorders
US20050171112A1 (en) *	2003-11-03	2005-08-04	Probiodrug Ag	Combinations useful for the treatment of neuronal disorders
US20100099721A1 (en) *	2003-11-03	2010-04-22	Probiodrug Ag	Novel compounds for the treatment of neurological disorders
US7667044B2 (en)	2003-11-03	2010-02-23	Probiodrug Ag	Compounds for the treatment of neurological disorders
US7304086B2 (en)	2004-02-05	2007-12-04	Probiodrug Ag	Inhibitors of glutaminyl cyclase
US7728031B2 (en) *	2006-02-24	2010-06-01	Abbott Laboratories	Octahydro-pyrrolo[3,4-b]pyrrole derivatives
US9108948B2 (en)	2006-06-23	2015-08-18	Abbvie Inc.	Cyclopropyl amine derivatives
UA98772C2 (ru)	2006-06-23	2012-06-25	Эбботт Леборетриз	Производные циклопропиламина как модуляторы н3-гистаминового рецептора
WO2008034891A2 (en)	2006-09-21	2008-03-27	Probiodrug Ag	Novel genes related to glutaminyl cyclase
US8889709B2 (en)	2006-09-21	2014-11-18	Probiodrug Ag	Use of isoQC inhibitors in the treatment and prevention of inflammatory diseases or conditions
US9277737B2 (en)	2006-09-21	2016-03-08	Probiodrug Ag	Mouse models carrying a knock-out mutation of the QPCTL-gene
US8420684B2 (en)	2006-11-09	2013-04-16	Probiodrug Ag	Inhibitors of glutaminyl cyclase
US8278345B2 (en)	2006-11-09	2012-10-02	Probiodrug Ag	Inhibitors of glutaminyl cyclase
EP2086960B1 (en)	2006-11-09	2014-03-05	Probiodrug AG	Novel inhibitors of glutaminyl cyclase
US9126987B2 (en)	2006-11-30	2015-09-08	Probiodrug Ag	Inhibitors of glutaminyl cyclase
GB2447017A (en) *	2007-03-01	2008-09-03	Probiodrug Ag	New use for inhibitors of glutaminyl peptide cyclotransferinase
CN101668525A (zh) *	2007-03-01	2010-03-10	前体生物药物股份公司	谷氨酰胺酰环化酶抑制剂的新用途
US7803810B2 (en) *	2007-03-09	2010-09-28	Probiodrug Ag	Inhibitors
JP5675341B2 (ja)	2007-04-18	2015-02-25	プロビオドルグエージー	グルタミニルシクラーゼ阻害剤としてのチオキソキナゾリノン誘導体
EP2142514B1 (en)	2007-04-18	2014-12-24	Probiodrug AG	Thiourea derivatives as glutaminyl cyclase inhibitors
JP5675342B2 (ja)	2007-04-18	2015-02-25	プロビオドルグエージー	グルタミニルシクラーゼ阻害剤としてのシアノグアニジン誘導体
JP5675343B2 (ja)	2007-04-18	2015-02-25	プロビオドルグエージー	グルタミニルシクラーゼ阻害剤としての尿素誘導体
ES2473621T3 (es)	2007-04-18	2014-07-07	Probiodrug Ag	Derivados de nitrovinil-diamina como inhibidores de glutaminil ciclasa
WO2008128981A1 (en) *	2007-04-18	2008-10-30	Probiodrug Ag	Nitrovinyl-diamine derivatives as glutaminyl cyclase inhibitors
JP5676249B2 (ja)	2007-04-20	2015-02-25	プロビオドルグエージー	グルタミニルシクラーゼ阻害剤としてのアミノピリジン誘導体
CA2691782A1 (en) *	2007-09-11	2009-03-19	Abbott Laboratories	Octahydro-pyrrolo[3,4-b]pyrrole n-oxides
CN101802000A (zh)	2007-09-12	2010-08-11	前体生物药物股份公司	转基因小鼠
AU2009204864A1 (en)	2008-01-14	2009-07-23	Probiodrug Ag	Mouse models carrying a knock-out mutation of the glutaminyl cyclase gene
JP5677297B2 (ja) *	2008-07-31	2015-02-25	プロビオドルグエージー	神経変性疾患の診断／予後判定の指標としてのグルタミニルシクラーゼ
US9186353B2 (en)	2009-04-27	2015-11-17	Abbvie Inc.	Treatment of osteoarthritis pain
BR112012008346B1 (pt)	2009-09-11	2021-12-21	Vivoryon Therapeutics N.V.	Derivados heterocíclicos, seu processo de preparação, e composição farmacêutica
WO2011101433A1 (en)	2010-02-18	2011-08-25	Probiodrug Ag	Methods of diagnosing inflammatory diseases by determining pyroglutamate-modified mcp-1 and screening methods for inhibitors of glutaminyl cyclase
EP2542549B1 (en)	2010-03-03	2016-05-11	Probiodrug AG	Inhibitors of glutaminyl cyclase
KR101790806B1 (ko)	2010-03-10	2017-11-20	프로비오드룩 아게	글루타미닐 사이클라제(ｑｃ, ｅｃ 2.3.2.5)의 헤테로사이클릭 억제제
EP2560953B1 (en)	2010-04-21	2016-01-06	Probiodrug AG	Inhibitors of glutaminyl cyclase
ES2540467T3 (es)	2010-08-19	2015-07-09	Probiodrug Ag	Estructura cristalina de glutaminil ciclasa
US8853390B2 (en)	2010-09-16	2014-10-07	Abbvie Inc.	Processes for preparing 1,2-substituted cyclopropyl derivatives
ES2570167T3 (es)	2011-03-16	2016-05-17	Probiodrug Ag	Derivados de benzimidazol como inhibidores de glutaminil ciclasa
AU2016288230A1 (en) *	2015-07-02	2018-01-25	Horizon Orphan Llc	ADO-resistant cysteamine analogs and uses thereof
EP3747437A1 (en)	2017-07-24	2020-12-09	Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis	Treating pathological conditions by direct and indirect targeting of sirpa - cd47 interaction
EP3461819B1 (en)	2017-09-29	2020-05-27	Probiodrug AG	Inhibitors of glutaminyl cyclase
CN112816581A (zh) *	2020-12-30	2021-05-18	浙江大学	衍生化-固相萃取-液相色谱串联质谱检测饮用水中卤代醌亚胺的方法
CN112898286A (zh) *	2021-01-28	2021-06-04	中国药科大学	苯并噻吩类化合物或其可药用的盐、异构体及其制备方法、药物组合物和用途
KR20240024948A (ko)	2021-06-24	2024-02-26	인실리코 메디신 아이피 리미티드	질환의 치료를 위한 베타-락탐 유도체

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2961377A (en)	1957-08-05	1960-11-22	Us Vitamin Pharm Corp	Oral anti-diabetic compositions and methods
US3174901A (en)	1963-01-31	1965-03-23	Jan Marcel Didier Aron Samuel	Process for the oral treatment of diabetes
US3879541A (en)	1970-03-03	1975-04-22	Bayer Ag	Antihyperglycemic methods and compositions
US3960949A (en)	1971-04-02	1976-06-01	Schering Aktiengesellschaft	1,2-Biguanides
CH602612A5 (da)	1974-10-11	1978-07-31	Hoffmann La Roche
US4935493A (en)	1987-10-06	1990-06-19	E. I. Du Pont De Nemours And Company	Protease inhibitors
US5433955A (en)	1989-01-23	1995-07-18	Akzo N.V.	Site specific in vivo activation of therapeutic drugs
ES2113879T3 (es)	1990-01-24	1998-05-16	Douglas I Buckley	Analogos de glp-1 utiles para el tratamiento de diabetes.
DE69124371T2 (de)	1990-04-14	1997-06-12	New England Medical Center Inc	Typ-iv-dipeptidyl-aminopeptidase-inhibitoren
US5462928A (en)	1990-04-14	1995-10-31	New England Medical Center Hospitals, Inc.	Inhibitors of dipeptidyl-aminopeptidase type IV
US6517824B1 (en)	1990-05-14	2003-02-11	University Of Medicine & Denistry Of New Jersey	Polymer compositions comprising antifibrotic agents, and methods of treatment, pharmaceutical compositions, and methods of preparation therefor
WO1991017767A1 (en)	1990-05-21	1991-11-28	New England Medical Center Hospitals, Inc.	Method of treating inhibition of dipeptidyl aminopeptidase type iv
GB9115740D0 (en)	1991-07-20	1991-09-04	Smithkline Beecham Plc	Medicaments
DE69233671T2 (de)	1991-10-22	2007-10-18	New England Medical Center Hospitals, Inc., Boston	Inhibitoren der Dipeptidyl-Aminopeptidase vom Typ IV
BR9306190A (pt)	1992-04-01	1998-06-23	Univ Toledo	Composto composiçao farmacéutica e processo para tratar um indivíduo sofrendo de um distúrbio cognitivo ou uma deficiéncia na atençao ou estímulo
IL106998A0 (en)	1992-09-17	1993-12-28	Univ Florida	Brain-enhanced delivery of neuroactive peptides by sequential metabolism
WO1995011689A1 (en)	1993-10-29	1995-05-04	Trustees Of Tufts College	Use of inhibitors of dipeptidyl-aminopeptidase to block entry of hiv into cells
IL111785A0 (en)	1993-12-03	1995-01-24	Ferring Bv	Dp-iv inhibitors and pharmaceutical compositions containing them
EP0658568A1 (en)	1993-12-09	1995-06-21	Eli Lilly And Company	Glucagon-like insulinotropic peptides, compositions and methods
US5705483A (en)	1993-12-09	1998-01-06	Eli Lilly And Company	Glucagon-like insulinotropic peptides, compositions and methods
WO1995022327A1 (en)	1994-02-22	1995-08-24	Knoll Ag	Use of 1-(arylalkylaminoalkyl) imidazoles for treating neurological damage
US5543396A (en)	1994-04-28	1996-08-06	Georgia Tech Research Corp.	Proline phosphonate derivatives
US5552426A (en)	1994-04-29	1996-09-03	Eli Lilly And Company	Methods for treating a physiological disorder associated with β-amyloid peptide
US5512549A (en)	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5614379A (en)	1995-04-26	1997-03-25	Eli Lilly And Company	Process for preparing anti-obesity protein
US6448282B1 (en)	1995-05-30	2002-09-10	Gliatech, Inc.	1H-4(5)-substituted imidazole derivatives
AU711927B2 (en) *	1996-02-27	1999-10-21	Sankyo Company Limited	Isoxazole derivatives
DE122010000020I1 (de)	1996-04-25	2010-07-08	Prosidion Ltd	Verfahren zur Senkung des Blutglukosespiegels in Säugern
ZA974147B (en)	1996-05-14	1997-11-14	Novo Nordisk As	Somatostatin agonists and antagonists.
AU3224997A (en)	1996-05-29	1998-01-05	Prototek, Inc	Prodrugs of thalidomide and methods for using same as modulators of t-cell function
US6006753A (en)	1996-08-30	1999-12-28	Eli Lilly And Company	Use of GLP-1 or analogs to abolish catabolic changes after surgery
US5827898A (en)	1996-10-07	1998-10-27	Shaman Pharmaceuticals, Inc.	Use of bisphenolic compounds to treat type II diabetes
US6011155A (en)	1996-11-07	2000-01-04	Novartis Ag	N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
TW492957B (en)	1996-11-07	2002-07-01	Novartis Ag	N-substituted 2-cyanopyrrolidnes
AR016751A1 (es)	1996-11-22	2001-08-01	Athena Neurosciences Inc	Metodo para inhibir la liberacion del peptido beta-amiloide en una celula, composicion farmaceutica y compuestos utiles en dicho metodo
US6350467B1 (en) *	1996-12-31	2002-02-26	Antioxidant Pharmaceuticals Corp.	Pharmaceutical preparations of glutathione and methods of administration thereof
AU1362699A (en)	1997-10-21	1999-05-10	Cambridge Neuroscience, Inc.	Pharmaceutically active compounds and methods of use
EP2574336A1 (en)	1998-02-02	2013-04-03	Trustees Of Tufts College	Use of dipeptidylpeptidase inhibitors to regulate glucose metabolism
US5994379A (en)	1998-02-13	1999-11-30	Merck Frosst Canada, Inc.	Bisaryl COX-2 inhibiting compounds, compositions and methods of use
JP2002506075A (ja)	1998-03-09	2002-02-26	フォンダテッヒ・ベネルクス・ナムローゼ・フェンノートシャップ	セリンペプチダーゼ調節剤
DE19823831A1 (de)	1998-05-28	1999-12-02	Probiodrug Ges Fuer Arzneim	Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
US6355614B1 (en)	1998-06-05	2002-03-12	Point Therapeutics	Cyclic boroproline compounds
ES2188184T3 (es)	1998-06-12	2003-06-16	Sod Conseils Rech Applic	Compuestos de beta-carbolinas.
DE19828113A1 (de)	1998-06-24	2000-01-05	Probiodrug Ges Fuer Arzneim	Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19828114A1 (de)	1998-06-24	2000-01-27	Probiodrug Ges Fuer Arzneim	Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
WO2000001849A1 (en)	1998-07-02	2000-01-13	Invitro Diagnostics, Inc.	Methods, compositions and apparatus for making nucleic acid molecules having a selected affinity to a target molecule
DE19834591A1 (de)	1998-07-31	2000-02-03	Probiodrug Ges Fuer Arzneim	Verfahren zur Steigerung des Blutglukosespiegels in Säugern
WO2000007617A1 (en)	1998-07-31	2000-02-17	Novo Nordisk A/S	Use of glp-1 and analogues for preventing type ii diabetes
BR9913153A (pt)	1998-08-21	2001-05-15	Point Therapeutics Inc	Normalização da atividade do substrato
AU3960400A (en)	1999-03-05	2000-09-28	Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A.	Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv
US6211182B1 (en)	1999-03-08	2001-04-03	Schering Corporation	Imidazole compounds substituted with a six or seven membered heterocyclic ring containing two nitrogen atoms
ES2225107T3 (es)	1999-03-29	2005-03-16	Uutech Limited	Analogos del peptido inhibidor gastrico y su uso para el tratamiento de la diabetes.
WO2000066110A1 (en) *	1999-04-29	2000-11-09	Merck Patent Gmbh	Glycine cleavage system inhibitors as potential antipsychotics
US6110949A (en)	1999-06-24	2000-08-29	Novartis Ag	N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6107317A (en)	1999-06-24	2000-08-22	Novartis Ag	N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6172081B1 (en)	1999-06-24	2001-01-09	Novartis Ag	Tetrahydroisoquinoline 3-carboxamide derivatives
GB9917909D0 (en)	1999-07-31	1999-09-29	Synphar Lab Inc	Cysteine protease inhibitors
JP4907817B2 (ja)	1999-11-03	2012-04-04	エーエムアールテクノロジーインコーポレイテッド	ノルエピネフリン、ドーパミンおよびセロトニンの再取り込みを遮断するための、４−フェニル置換テトラヒドロイソキノリン類およびその利用
EP1228061A4 (en)	1999-11-12	2004-12-15	Guilford Pharm Inc	DIPEPTIDYL PEPTIDASE IV INHIBITORS; METHODS OF MANUFACTURE AND USE OF SAID INHIBITORS
GB9928330D0 (en)	1999-11-30	2000-01-26	Ferring Bv	Novel antidiabetic agents
US6380398B2 (en)	2000-01-04	2002-04-30	Novo Nordisk A/S	Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV
WO2001055105A1 (en)	2000-01-24	2001-08-02	Novo Nordisk A/S	N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv
EP1259246A2 (en)	2000-02-25	2002-11-27	Novo Nordisk A/S	Use of dpp-iv inhibitors for the treatment of diabetes
US7064145B2 (en)	2000-02-25	2006-06-20	Novo Nordisk A/S	Inhibition of beta cell degeneration
DE60042585D1 (de)	2000-02-29	2009-09-03	Univ Firenze	3-Aza-6,8-dioxabicycloÄ3.2.1Üoctane und Analoga sowie diese enthaltende kombinatorische Bibliotheken
US6395767B2 (en)	2000-03-10	2002-05-28	Bristol-Myers Squibb Company	Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US6605589B1 (en)	2000-03-31	2003-08-12	Parker Hughes Institute	Cathepsin inhibitors in cancer treatment
EP2266665B1 (en)	2000-03-31	2016-05-11	Royalty Pharma Collection Trust	Method for the improvement of islet signaling in diabetes mellitus and for its prevention
US6573096B1 (en)	2000-04-01	2003-06-03	The Research Foundation At State University Of New York	Compositions and methods for inhibition of cancer invasion and angiogenesis
GB0010188D0 (en)	2000-04-26	2000-06-14	Ferring Bv	Inhibitors of dipeptidyl peptidase IV
GB0010183D0 (en)	2000-04-26	2000-06-14	Ferring Bv	Inhibitors of dipeptidyl peptidase IV
US6841685B2 (en)	2000-06-07	2005-01-11	State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University	Methods for making bis-heterocyclic alkaloids
GB0014969D0 (en)	2000-06-19	2000-08-09	Smithkline Beecham Plc	Novel method of treatment
HUP0301622A3 (en)	2000-07-04	2006-05-29	Novo Nordisk As	Purine derivatives inhibiting the enzyme dipeptidyl petidase iv (dpp-iv) and pharmaceutical compositions containing them
WO2002004610A2 (en)	2000-07-10	2002-01-17	Bayer Aktiengesellschaft	Regulation of human dipeptidyl-peptidase iv-like enzyme
DE60140708D1 (de)	2000-08-10	2010-01-14	Mitsubishi Tanabe Pharma Corp	Prolinderivative und deren Verwendung als Medikamente
US6794405B2 (en)	2000-08-17	2004-09-21	Merck & Co., Inc.	Alicyclic imidazoles as H3 agents
ATE393141T1 (de)	2000-08-21	2008-05-15	Pacific Corp	Neue thiourea-derivate und pharmazeutische zusammensetzungen die diese enthalten
ATE475887T1 (de)	2000-09-09	2010-08-15	Univ New York State Res Found	Verfahren und zusammensetzungen zur isolierung von metastatischen krebszellen und anwendung zur messung des metastatischen potentials eines krebses
PT1328271E (pt)	2000-10-27	2008-08-26	Probiodrug Ag	Tratamento de distúrbios neurológicos e neuropsicológicos
TWI243162B (en)	2000-11-10	2005-11-11	Taisho Pharmaceutical Co Ltd	Cyanopyrrolidine derivatives
EP1354882A1 (en)	2000-12-27	2003-10-22	Kyowa Hakko Kogyo Co., Ltd.	Dipeptidyl peptidase iv inhibitor
JP2002226457A (ja) *	2001-02-02	2002-08-14	Ajinomoto Co Inc	新規シスチン誘導体及び炎症因子活性化抑制剤
SE0100566D0 (sv)	2001-02-20	2001-02-20	Astrazeneca Ab	Compounds
PT2298769E (pt)	2001-02-24	2013-11-29	Boehringer Ingelheim Pharma	Derivados de xantina, sua preparação e sua utilização como produto farmacêutico
US7026316B2 (en)	2001-03-27	2006-04-11	Merck & Co., Inc.	Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US6573287B2 (en)	2001-04-12	2003-06-03	Bristo-Myers Squibb Company	2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
US7053072B2 (en)	2001-05-11	2006-05-30	Medimmune Oncology, Inc.	Methods for the administration of amifostine and related compounds
US7098239B2 (en)	2001-06-20	2006-08-29	Merck & Co., Inc	Dipeptidyl peptidase inhibitors for the treatment of diabetes
DE60209348T2 (de)	2001-06-20	2006-10-12	Merck & Co., Inc.	Dipeptidylpeptidase-hemmer zur behandlung von diabetes
GB0115517D0 (en)	2001-06-25	2001-08-15	Ferring Bv	Novel antidiabetic agents
KR20040015298A (ko)	2001-06-27	2004-02-18	스미스클라인 비참 코포레이션	디펩티딜 펩티다제 억제제로서의 플루오로피롤리딘
EP1399469A2 (en)	2001-06-27	2004-03-24	Probiodrug AG	Peptide structures useful for competitive modulation of dipeptidyl peptidase iv catalysis
WO2003002530A2 (en)	2001-06-27	2003-01-09	Smithkline Beecham Corporation	Pyrrolidines as dipeptidyl peptidase inhibitors
DE10150203A1 (de)	2001-10-12	2003-04-17	Probiodrug Ag	Peptidylketone als Inhibitoren der DPIV
DE60221983T2 (de)	2001-06-27	2008-05-15	Smithkline Beecham Corp.	Fluorpyrrolidine als dipeptidyl-peptidase inhibitoren
WO2003002595A2 (en)	2001-06-27	2003-01-09	Probiodrug Ag	Dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents
JP2005502624A (ja)	2001-07-03	2005-01-27	ノボ　ノルディスク　アクティーゼルスカブ	糖尿病を治療するための、ｄｐｐ−ｉｖを阻害するプリン誘導体
US6948038B2 (en) *	2001-07-24	2005-09-20	Microsoft Corporation	System and method for backing up and restoring data
EP1417220A2 (en)	2001-08-13	2004-05-12	Probiodrug AG	Irreversible cysteine protease inhibitors of legumain
KR20040033048A (ko)	2001-09-14	2004-04-17	미츠비시 웰파마 가부시키가이샤	티아졸리딘 유도체 및 이의 약학적 용도
AU2002331311A1 (en)	2001-09-19	2003-04-01	Novo Nordisk A/S	Heterocyclic compounds that are inhibitors of the enzyme dpp-iv
GB0125446D0 (en)	2001-10-23	2001-12-12	Ferring Bv	Novel anti-diabetic agents
AU2003219690A1 (en)	2002-02-19	2003-09-09	Pharmacia And Upjohn Company	Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease
BRPI0409241A (pt)	2003-04-10	2006-03-28	Pfizer	compostos bicìclicos como antagonistas do receptor de nr2b, composições farmacêuticas compreendendo os mesmos e seu uso
ATE464889T1 (de) *	2003-05-05	2010-05-15	Probiodrug Ag	Medizinische verwendung von hemmern von glutaminyl und glutamatcyclasen
ZA200508439B (en)	2003-05-05	2007-03-28	Probiodrug Ag	Medical use of inhibitors of glutaminyl and glutamate cyclases
KR20110059664A (ko)	2003-05-05	2011-06-02	프로비오드룩 아게	글루타미닐 및 글루타메이트 사이클라제의 이펙터의 용도
US7732162B2 (en)	2003-05-05	2010-06-08	Probiodrug Ag	Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
US8338120B2 (en)	2003-05-05	2012-12-25	Probiodrug Ag	Method of treating inflammation with glutaminyl cyclase inhibitors
MXPA06003998A (es)	2003-10-15	2006-06-27	Probiodrug Ag	Uso de efectores de ciclasas de glutamato y glutaminil.
WO2005059100A2 (en) *	2003-12-12	2005-06-30	New York University	Methods and compositions relating to cystatin c
GB0704100D0 (en)	2006-03-17	2007-04-11	Vodafone Plc	Improvements in an ehspa architecture

2004
- 2004-10-15 MX MXPA06003998A patent/MXPA06003998A/es active IP Right Grant
- 2004-10-15 BR BRPI0415409-6A patent/BRPI0415409A/pt not_active IP Right Cessation
- 2004-10-15 CN CN2011102597085A patent/CN102302781A/zh active Pending
- 2004-10-15 EA EA200600618A patent/EA010108B1/ru not_active IP Right Cessation
- 2004-10-15 EP EP10177029A patent/EP2289498A1/en not_active Withdrawn
- 2004-10-15 DK DK04765975.0T patent/DK1675578T3/da active
- 2004-10-15 KR KR1020127024628A patent/KR101313975B1/ko not_active Expired - Fee Related
- 2004-10-15 JP JP2006534704A patent/JP5707014B2/ja not_active Expired - Fee Related
- 2004-10-15 AU AU2004283461A patent/AU2004283461B2/en not_active Ceased
- 2004-10-15 WO PCT/EP2004/011630 patent/WO2005039548A2/en active Application Filing
- 2004-10-15 US US10/966,645 patent/US7462599B2/en active Active
- 2004-10-15 CN CNA2004800302025A patent/CN1867324A/zh active Pending
- 2004-10-15 KR KR1020117031195A patent/KR20120007079A/ko not_active Ceased
- 2004-10-15 EP EP04765975.0A patent/EP1675578B9/en not_active Expired - Lifetime
- 2004-10-15 CA CA2542419A patent/CA2542419C/en not_active Expired - Fee Related
- 2004-10-15 KR KR1020067007310A patent/KR101121882B1/ko not_active Expired - Fee Related
- 2004-10-15 NZ NZ546322A patent/NZ546322A/en not_active IP Right Cessation
2006
- 2006-03-16 IL IL174372A patent/IL174372A/en not_active IP Right Cessation
2008
- 2008-07-29 US US12/182,113 patent/US8470781B2/en active Active
2014
- 2014-10-20 JP JP2014213807A patent/JP2015057400A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
CA2542419C (en)	2013-06-04
EP1675578B1 (en)	2013-05-22
JP2015057400A (ja)	2015-03-26
AU2004283461B2 (en)	2010-02-11
US8470781B2 (en)	2013-06-25
BRPI0415409A (pt)	2006-12-05
JP2007508347A (ja)	2007-04-05
IL174372A0 (en)	2006-08-01
CN102302781A (zh)	2012-01-04
EP1675578B9 (en)	2014-06-25
KR101313975B1 (ko)	2013-10-01
KR20120007079A (ko)	2012-01-19
JP5707014B2 (ja)	2015-04-22
NZ546322A (en)	2008-11-28
WO2005039548A2 (en)	2005-05-06
CN1867324A (zh)	2006-11-22
WO2005039548A3 (en)	2005-06-30
IL174372A (en)	2011-09-27
KR20120125379A (ko)	2012-11-14
AU2004283461A2 (en)	2005-05-06
EP1675578A2 (en)	2006-07-05
KR20070017477A (ko)	2007-02-12
EP2289498A1 (en)	2011-03-02
US20060189523A1 (en)	2006-08-24
CA2542419A1 (en)	2005-05-06
AU2004283461A1 (en)	2005-05-06
EA010108B1 (ru)	2008-06-30
US20090149394A1 (en)	2009-06-11
KR101121882B1 (ko)	2012-04-12
US7462599B2 (en)	2008-12-09
MXPA06003998A (es)	2006-06-27
EA200600618A1 (ru)	2006-10-27

Publication	Publication Date	Title
DK1675578T3 (da)	2013-08-26	Inhibitorer af glutaminyl- og glutamatcyclaser til behandling af de neurodegenerative sygdomme FBD og FDD
DK1663978T3 (da)	2008-04-07	Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
IS8246A (is)	2006-01-19	Meðferð á taugahrörnunarástandi
DK2308507T3 (da)	2015-04-20	Fremgangsmåder til behandling af præeklampsi
DK1644021T3 (da)	2012-10-29	Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
DK1824475T3 (da)	2011-06-06	Fremgangsmåde til oprensning af trans-(-)-delta9-tetrahydrocannabinol og trans-(+)-delta9-tetrahydrocannabinol
IS7977A (is)	2005-08-12	Samsetningar og aðferð til samsettra meðferðar
DK1803718T3 (da)	2008-10-27	4-Tetrazolyl-4-phenylpiperidin-derivater til behandling af smerter
DK1667986T3 (da)	2013-05-06	Acetonesolvat af dimethoxydocetaxel og fremgangsmåde til fremstilling heraf
DK1888033T3 (da)	2014-05-26	Fremgangsmåde og sammensætning til behandling af inflammatoriske sygdomme
DK1853271T3 (da)	2011-01-24	Fremgangsmåde og præparat til behandling af perifere vaskulære sygdomme
IS8142A (is)	2005-11-23	Læknislyf gagnleg til meðferðar á verkjum
IL175535A (en)	2016-03-31	Compositions for treatment of neurodegenerative diseases
DK1506041T3 (da)	2008-01-28	Inbandronsyre til behandling og forebyggelse af osteoporose
GB2415378B (en)	2006-08-02	Treatment of neurodegenerative conditions
IS8497A (is)	2006-06-02	Aðferðir og hvarfefni til að meðhöndla bólgusjúkdóma
DK1919290T3 (da)	2014-04-22	Fremgangsmåder og produkter til behandling af sygdomme
DK1601744T3 (da)	2012-08-20	Forgasningsapparat og fremgangsmåde
DK1599469T3 (da)	2006-10-09	Tetrazolderivater og fremgangsmåder til behandling af metabolismerelaterede forstyrrelser dermed
DK1589973T4 (da)	2013-04-08	Formulering og fremgangsmåder til behandling af thrombocytæmi
DK1727801T3 (da)	2009-05-11	Til behandling af smerter anvendelige piperaziner
DK1687297T3 (da)	2014-09-22	Triazindimerer til behandling af autoimmunsygdomme
EP1558276A4 (en)	2006-09-13	FLAVIVIRIS FUSION INHIBITORS
AU2003259833A8 (en)	2004-03-03	Methods of treating neurodegenerative diseases
GB0300783D0 (en)	2003-02-12	Treatment of neurodegenerative conditions